Eton Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 94 the day before.
Discover The 3 Keys To Successful Stock Investing
The new score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
Eton Pharmaceuticals is currently extended beyond a proper buy zone after breaking out from an 18.31 buy point in a cup with handle. Note that it is a thinly traded stock, with average daily dollar volume under $8 million.
The stock earns an 80 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company posted a 0% increase in earnings for Q2. Revenue growth fell to 109%, down from 117% in the previous quarter.
Eton Pharmaceuticals holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
